MTL CEBPA

Drug Profile

MTL CEBPA

Alternative Names: MTL-CEBPA

Latest Information Update: 17 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MiNA Therapeutics; University of California at San Francisco; University of Texas Southwestern Medical Center
  • Developer MiNA Therapeutics
  • Class Antineoplastics; Oligonucleotides; RNA
  • Mechanism of Action RNA stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Liver cancer

Most Recent Events

  • 29 Nov 2016 Pharmacodynamics data from a preclinical study in Liver cancer presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2016)
  • 14 Nov 2016 Updated pharmacodynamics data from preclinical study in Pancreatic cancer released by MiNA Therapeutics
  • 11 Nov 2016 Updated pharmacodynamics data from a preclinical study in Liver cancer presented at the 67th Annual Meeting of the American Association for the Study of Liver Diseases (AALD-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top